Loading
Pairidex makes a personalised blood test that tracks the gene fusion driving a person's leukaemia, so their doctors can see how well treatment is working and spot a return of the disease early.
Pairidex is a St. Louis company developing FusionMRD, a personalised droplet digital PCR assay that detects the gene fusion driving an individual patient's blood cancer, for monitoring treatment response and long-term surveillance of measurable residual disease. It starts with fusion-driven acute myeloid leukaemia and runs the test in a CLIA-certified, CAP-accredited laboratory. Andrew Young is founder and chief scientific officer. In February 2026 it announced a pre-seed lead investment from BioGenerator Ventures, and in July 2026 it closed an oversubscribed seed round bringing in USD 4.89 million to support the commercial launch of FusionMRD; the company described the seed investor only as a large, publicly held strategic company.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Pre-seed · Led by BioGenerator Ventures; amount not disclosed | 2026 | undisclosed | pairidex.com |
| Seed · Oversubscribed; investor not named | 2026 | $5M | pairidex.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/